

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康集團

Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

**COMPLETION OF ISSUE OF SHARES
UNDER GENERAL MANDATE**

The Board is pleased to announce that the conditions set out in the Subscription Agreement have been fulfilled and Completion took place on 6 August 2019 in accordance with the terms and conditions of the Subscription Agreement.

The total number of 215,800,000 Subscription Shares allotted and issued to the Subscriber at the Subscription Price of HK\$0.139 per Subscription Share represented approximately 3.37% of the issued share capital of the Company as enlarged by the issue of the Subscription Shares. The Company received net proceeds of approximately HK\$29.9 million from the Subscription.

Reference is made to the announcement of Uni-Bio Science Group Limited (“**Company**”) dated 22 July 2019 (“**Announcement**”) in relation to, inter alia, the proposed issue of shares under General Mandate. Terms used herein shall have the same meanings as those defined in the Announcement unless defined otherwise.

* For identification purposes only

The Board is pleased to announce that the conditions set out in the Subscription Agreement have been fulfilled and Completion took place on 6 August 2019 in accordance with the terms and conditions of the Subscription Agreement.

The total number of 215,800,000 Subscription Shares allotted and issued to the Subscriber at the Subscription Price of HK\$0.139 per Subscription Share represented approximately 3.37% of the issued share capital of the Company as enlarged by the issue of the Subscription Shares. The Company received net proceeds of approximately HK\$29.9 million from the Subscription.

The shareholding structure of the Company (1) immediately before Completion; and (2) immediately after Completion are as follows:

Shareholders	(1) Immediately before Completion		(2) Immediately after Completion	
	<i>Number of Shares</i>	<i>%</i>	<i>Number of Shares</i>	<i>%</i>
Automatic Result				
Limited (<i>Note 1</i>)	736,301,016	11.89	736,301,016	11.48
Lord Profit Limited (<i>Note 2</i>)	914,576,010	14.76	914,576,010	14.27
Overseas Capital				
Assets Limited (<i>Note 3</i>)	657,180,000	10.61	657,180,000	10.25
Vital Vigour Limited (<i>Note 4</i>)	873,360,000	14.10	873,360,000	13.62
Chen Dawei (<i>Note 5</i>)	345,955,516	5.58	345,955,516	5.40
The Subscriber	–	–	215,800,000	3.37
Other Shareholders	2,667,595,605	43.06	2,667,595,605	41.61
Total	6,194,968,147	100.00	6,410,768,147	100.00

Notes:

- Automatic Result Limited is wholly owned by MJKPC Holdings Limited, which is a family trust which Mr. Kingsley Leung, an executive Director and chairman of the Board, is one of the discretionary objects.
- Lord Profit Limited is wholly owned by Mr. Kingsley Leung.
- Based on the individual substantial shareholder notice of Overseas Capital Assets Limited filed on 19 June 2014, Overseas Capital Assets Limited is wholly owned by He Rufeng.
- Vital Vigour Limited is a wholly-owned subsidiary of HeungKong Great Health GP Limited, which is acting for and on behalf of, and as the general partner of, HeungKong Great Health Fund I.
- Mr. Chan Dawei is an executive Director and vice-chairman of the Board.

6. Certain percentage figures included in the above tables have been subject to rounding adjustments. Accordingly, figures shown as totals may not be an arithmetic aggregation of the figures preceding them.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 6 August 2019

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman) and Mr. Zhao Zhi Gang; one non-executive Director, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.